Roflumilast is a novel, potent, selective phosphodiesterase 4 (PDE4) inhibitor for the treatment of chronic obstructive pulmonary disease (COPD) and asthma (fig. This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.